hassan almarhabi - Infectious Diseases

Author Information

Hassan Almarhabi is affiliated with prestigious institutions in Saudi Arabia. He is associated with the King Saud Bin Abdulaziz University for Health Sciences and the King Abdullah International Medical Research Center. Additionally, he serves in the Department of Internal Medicine and the Department of Infectious Diseases at King Abdulaziz Medical City, under the Ministry of National Guard Health Affairs in Jeddah, Saudi Arabia. His work primarily focuses on infectious diseases, contributing significantly to the healthcare and research community in the region.

Research Contributions

Hassan Almarhabi has made substantial contributions to the field of infectious diseases. His research encompasses a variety of topics, including melioidosis pneumonia, cytomegalovirus infections, sepsis notification systems, COVID-19 treatment trials, and invasive mucormycosis. Notably, his work on electronic early notification of sepsis and COVID-19 treatment trials with Favipiravir and Hydroxychloroquine has been recognized in multiple studies. His research is vital for advancing understanding and treatment of infectious diseases in both regional and global contexts.

Aliases

Hassan Almarhabi is the name used consistently across his publications and affiliations. There are no additional aliases provided for him in the records.

Publication and Citation Metrics

Metric	Value
Total Papers Published	10
Total Citation Count	22
h-index	3

Publications:

Melioidosis Pneumonia in Saudi Arabia: A Rare Case Report and Review of the Literature

DOI: 10.7759/cureus.21871

Year: 2022

Simultaneous Occurrence of Cytomegalovirus Colitis and Retinitis as the Initial Presentation of Human Immunodeficiency Virus Infection in a Patient With Zero CD4 Count

DOI: 10.7759/cureus.22455

Year: 2022

Statistical analysis plan for the Steppedwedge Cluster Randomized trial of Electronic Early Notification of sepsis in hospitalized ward patients (SCREEN)

DOI: 10.1186/s13063-021-05788-3

Year: 2021

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

DOI: 10.1007/s40121-021-00496-6

Year: 2021

Electronic early notification of sepsis in hospitalized ward patients: a study protocol for a stepped-wedge cluster randomized controlled trial

DOI: 10.1186/s13063-021-05562-5

Year: 2021

977. Invasive Mucormycosis in a Tertiary Care Hospital, Western Saudi Arabia: 11-Year Retrospective Chart Review, from 2009 – 2019

DOI: 10.1093/ofid/ofab466.1171

Year: 2021

Electronic early notification of sepsis in hospitalized ward patients: a study protocol for a stepped-wedge cluster randomized controlled trial

DOI: 10.1101/2021.05.20.21257511

Year: 2021

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT): An Open-Label, Multicentre, Randomised, Controlled Trial

DOI: 10.2139/SSRN.3829663

Year: 2021

Symptomatic BK virus cystitis in non-renal transplant recipients

DOI: 10.3138/JAMMI.2018-0035

Year: 2019

What are MHC Genes?

Is There a Treatment?

What Techniques Are Used to Study Genomic Structure?

How Does Host Fatty Acid Biosynthesis Interact with Pathogens?

How is Gene Therapy Applied in Infectious Diseases?

How is Protein Targeting Relevant to Infectious Diseases?

Can Herpes Affect Mental Health?

How does it spread?

What Research is Being Conducted on Apicoplasts?

How do condoms prevent infectious diseases?

Partnered Content Networks

Relevant Topics